OTCMKTS:OPHLY Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free OPHLY Stock Alerts $4.86 +0.07 (+1.46%) (As of 04/26/2024 08:54 PM ET) Add Compare Share Share Today's Range$4.80▼$4.8650-Day Range$4.79▼$5.5952-Week Range$4.71▼$6.85Volume121,400 shsAverage Volume102,321 shsMarket CapitalizationN/AP/E Ratio1.06Dividend Yield340.68%Price TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Ono Pharmaceutical alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Ono Pharmaceutical Stock (OTCMKTS:OPHLY)Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.Read More OPHLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OPHLY Stock News HeadlinesMarch 6, 2024 | msn.comOno signs licence deal with NEX-I for cancer therapyFebruary 26, 2024 | finance.yahoo.comFate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial ResultsApril 29, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…February 19, 2024 | markets.businessinsider.comInveniAI Announces Collaboration with Ono Pharmaceutical for Target DiscoveryFebruary 15, 2024 | finance.yahoo.comOno Pharmaceutical Co., Ltd. (OPHLY)February 14, 2024 | globenewswire.comNumab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of CancerFebruary 10, 2024 | barrons.comOno Pharmaceutical Co. Ltd.January 30, 2024 | markets.businessinsider.comOno Pharmaceutical earnings preview: what Wall Street is expectingApril 29, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…January 9, 2024 | finance.yahoo.comCall for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed XDecember 19, 2023 | finanznachrichten.deThe BioMed X Institute: BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer ResearchNovember 28, 2023 | finance.yahoo.comNikkei Edges 0.2% Lower Amid JPY StrengthNovember 27, 2023 | finance.yahoo.comChina Shares Open Lower; Infrastructure Stocks WeighOctober 5, 2023 | msn.comOno Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Increased by 10.78% to 7.59August 31, 2023 | finance.yahoo.comTwist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune DiseasesAugust 31, 2023 | markets.businessinsider.comTwist Bioscience To Develop Novel Antibodies With Ono PharmaAugust 9, 2023 | finance.yahoo.comQ2 2023 Fate Therapeutics Inc Earnings CallAugust 3, 2023 | msn.comOno Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Decreased by 29.33% to 6.89March 23, 2023 | technews.tmcnet.comMacomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of CancerNovember 1, 2022 | benzinga.comMemo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology TargetsSeptember 19, 2022 | finance.yahoo.com3 Reasons Why Ono Pharmaceutical Co. (OPHLF) Is a Great Growth StockAugust 30, 2022 | seekingalpha.comFate Therapeutics: Yes For Speculators, No For Defensive InvestorsJuly 18, 2022 | benzinga.comOno Pharmaceutical (OTC:OPHLY), Earnings Estimates, EPS, and RevenueJuly 18, 2022 | benzinga.comOno Pharmaceutical (OTC:OPHLY), Analyst Ratings, Price Targets, PredictionsJuly 7, 2022 | uk.finance.yahoo.comCan Ono Pharmaceutical Co ride out the impact of economic shocks?January 23, 2022 | nasdaq.comOno Pharmaceutical Co. Ltd ADR (OPHLY)November 8, 2021 | markets.businessinsider.comHere's what to expect from ONO PHARMACEUTICAL's earnings reportSee More Headlines Receive OPHLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:OPHLY CUSIPN/A CIK940821 Webwww.ono.co.jp Phone(166) 263-5670FaxN/AEmployees3,761Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio1.06 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Gyo Sagara (Age 66)CEO, President & Representative Director Comp: $894.2kMr. Masaki ItoCorp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. TaxTakehiro YamadaCorporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion OfficeMasayuki TanigawaCorporate Officer & Executive Director of Corporate Development & StrategyMr. Toichi Takino Ph.D. (Age 56)Senior Managing Executive Officer, Head of Research Division & Director Mr. Toshihiro Tsujinaka (Age 60)Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director Hiromu Habashita Ph.D.Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of ImmunologyKiyoaki Idemitsu (Age 60)Managing Executive Officer, GM of Development Division & Director Shinji Takai M.D.Ph.D., Corporate Officer & Head of Medical AffairsSatoshi TakahagiCorporate Officer and Executive Director of Sales, Marketing & Primary Care Business DivisionMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDaiichi SankyoOTCMKTS:DSNKYDechra PharmaceuticalsOTCMKTS:DCHPFView All Competitors OPHLY Stock Analysis - Frequently Asked Questions How have OPHLY shares performed in 2024? Ono Pharmaceutical's stock was trading at $5.86 at the start of the year. Since then, OPHLY shares have decreased by 17.1% and is now trading at $4.86. View the best growth stocks for 2024 here. Are investors shorting Ono Pharmaceutical? Ono Pharmaceutical saw a increase in short interest in April. As of April 15th, there was short interest totaling 46,500 shares, an increase of 123.6% from the March 31st total of 20,800 shares. Based on an average trading volume of 235,500 shares, the short-interest ratio is presently 0.2 days. View Ono Pharmaceutical's Short Interest. Is Ono Pharmaceutical a good dividend stock? Ono Pharmaceutical (OTCMKTS:OPHLY) pays an annual dividend of $16.56 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 362.62%. Payout ratios above 75% are not desirable because they may not be sustainable. How do I buy shares of Ono Pharmaceutical? Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OPHLY) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressGreat Crypto BullWeiss RatingsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
